Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) has been given a consensus recommendation of “Buy” by the seven analysts that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $43.14.
Several equities research analysts recently issued reports on NRIX shares. HC Wainwright dropped their price objective on Nurix Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Thursday, April 14th. Piper Sandler dropped their price target on Nurix Therapeutics from $55.00 to $35.00 in a research note on Tuesday, May 31st. Royal Bank of Canada dropped their price target on Nurix Therapeutics from $42.00 to $39.00 and set an “outperform” rating for the company in a research note on Monday, April 18th. Needham & Company LLC dropped their price target on Nurix Therapeutics from $48.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, May 27th. Finally, Wells Fargo & Company raised Nurix Therapeutics from an “equal weight” rating to an “overweight” rating and set a $25.00 price target for the company in a research note on Tuesday, May 31st.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NRIX. Geode Capital Management LLC lifted its stake in shares of Nurix Therapeutics by 59.8% in the 3rd quarter. Geode Capital Management LLC now owns 630,698 shares of the company’s stock valued at $18,895,000 after acquiring an additional 235,941 shares during the last quarter. Credit Suisse AG lifted its stake in shares of Nurix Therapeutics by 32.8% in the 3rd quarter. Credit Suisse AG now owns 13,698 shares of the company’s stock valued at $411,000 after acquiring an additional 3,385 shares during the last quarter. Natixis purchased a new position in Nurix Therapeutics during the 3rd quarter valued at about $255,000. Mariner LLC purchased a new position in Nurix Therapeutics during the 3rd quarter valued at about $869,000. Finally, Guggenheim Capital LLC purchased a new position in Nurix Therapeutics during the 3rd quarter valued at about $201,000. 89.94% of the stock is owned by institutional investors.
Nurix Therapeutics (NASDAQ:NRIX – Get Rating) last posted its quarterly earnings data on Thursday, April 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.06). The business had revenue of $9.62 million for the quarter, compared to the consensus estimate of $8.77 million. Nurix Therapeutics had a negative net margin of 394.21% and a negative return on equity of 38.11%. On average, equities analysts predict that Nurix Therapeutics will post -3.93 earnings per share for the current year.
Nurix Therapeutics Company Profile (Get Rating)
Nurix Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
- Get a free copy of the StockNews.com research report on Nurix Therapeutics (NRIX)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.